Galcanezumab

Galcanezumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCALCA, CALCB
Clinical data
Trade namesEmgality
Other namesLY2951742, galcanezumab-gnlm
AHFS/Drugs.comMonograph
MedlinePlusa618063
License data
Routes of
administration		Subcutaneous
Drug classCalcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6392H9854N1686O2018S46
Molar mass144083.69 g·mol−1

Galcanezumab,[4][5] sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[2] It is also used for the treatment of cluster headaches.[6]

A substance called calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain.[3] Galcanezumab is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size.[3] This will stop the symptoms of migraine.[3] Galcanezumab is generally delivered through self-injections.[7] Common side effects include injection site reactions such as pain or redness.[6][3] Other side effects may include hypersensitivity reactions.[6]

Galcanezumab was developed by Eli Lilly.[8] It was approved for medical use in the United States and in the European Union in 2018,[9][10][3] becoming the third calcitonin gene-related peptide (CGRP) inhibitor to be approved by the US Food and Drug Administration (FDA).[11]

  1. ^ "Summary Basis of Decision (SBD) for Emgality". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ a b "Emgality- galcanezumab-gnlm injection, solution". DailyMed. 11 March 2021. Retrieved 29 April 2024.
  3. ^ a b c d e f Cite error: The named reference Emgality EPAR was invoked but never defined (see the help page).
  4. ^ "Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.
  5. ^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.
  6. ^ a b c "FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks" (Press release). U.S. Food and Drug Administration (FDA). 4 June 2019. Archived from the original on 7 December 2019. Retrieved 6 June 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ "Galcanezumab-gnlm Injection: MedlinePlus Drug Information". medlineplus.gov. Retrieved 26 July 2024.
  8. ^ Spreitzer H (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
  9. ^ "Drug Approval Package: Emgality (galcanezumab-gnlm)". U.S. Food and Drug Administration (FDA). 27 September 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019.
  10. ^ "Drug Trials Snapshots: Emgality". U.S. Food and Drug Administration (FDA). 23 October 2018. Archived from the original on 7 December 2019. Retrieved 7 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.